Next, with the aim to mimic a clinical therapeutic scenario, we assessed TIM3 blockade therapy in a neoadjuvant/adjuvant (NA/A) setting to reduce and prevent breast cancer metastasis. The gene discussed is HAVCR2; the disease is breast cancer.